Report Highlights
The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.
Report Includes
- 15 data tables and 22 additional tables
- An in-depth overview and industry analysis of the global market for neurology medicines
- Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Historical background on neurological disorders and therapeutics, growing prevalence of neurological disorders, increasing research and development activities regarding neurology research, and analysis of the factors influencing the market
- Quantitative analysis of the neurology therapeutics market covering Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases
- Discussion of various therapeutics used for treatment of different neurological disorders, along with coverage of novel pipeline, patent expiry of blockbuster drug and new drug approvals
- Reviews of the competitive landscape, key strategies adopted by market players, mergers and acquisitions details, pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage etc.
- Details company profile of leading participants within the neurology market including, AbbVie, Biogen, GlaxoSmithKline Plc, Johnson & Johnson, and Sun Pharmaceuticals Industries Ltd.
Report Scope
The scope of this report is broad and covers therapeutics used in treatment of neurological disorders.
The report highlights the current and future market potential of neurology medicines and provides a detailed analysis of the competitive environment, regulations, epidemiology of neurological diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.
The report details market shares of neurology based on different disease indication. Based on neurological disorders the market is segmented into Parkinson Diseases, Alzheimer Diseases, Psychotic Disorders, Epileptic Disorders, Autism Disorders, and Brain Tumor Diseases. Each diseases segment covers therapeutics and regional analysis.
The market of Parkinson Diseases covers anti-Parkinson’s drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into dopaminergic, enzyme inhibitors, dopamine agonists and other Anti-Parkinson’s medications. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Alzheimer Diseases covers anti-Alzheimer drugs. the market is segmented based on mechanism of action of drugs and region. based on drug class the market is segmented into AChE inhibitors and NMDA antagonist. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of psychotic diseases covers antipsychotic drugs. The market is segmented into drug class and region. Based on drug, the market is segmented into D2 antagonists, D2/5HT2A antagonists, and D2 partial agonist. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of Epileptic Diseases covers Anti-Epileptic Drugs. The market is segmented into drug class and region. Based on drug class the market is segmented into first generation drugs, second generation drugs, and third generation drugs. Based on region the market is segmented into North America, Europe, Asia-Pacific, South America and Middle East and Africa.
The market of autism disorder covers autism disorder therapeutics. The market is segmented into drug based on labelled information and region. Based on drug class the market is segmented into ASD-labeled pharmaceuticals and Off-label pharmaceuticals. Based on region the market is segmented into North America, Europe, and Rest of the World.
The market of brain tumor covers brain tumor therapeutics. The market is segmented into therapy type and region. Based on therapy type, the market is segmented into chemotherapy and targeted therapy. Based on region, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.
For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Artificial Intelligence (AI) in Cancer (BIO196B)
- Nutraceuticals: Global Markets (FOD013J)
- Protective Relays and Circuit Breakers: Global Markets (IAS157B)
- Global Market Opportunities and Competitive Landscape for CDMO (PHM238B)
- Flow Batteries: Global Markets (FCB055B)
Related Reports
Theranostics: Global Markets
The global market for theranostics was valued at $3.7 billion in 2023. The market is expected to grow from $4.3 billion in 2024 to $12.7 billion by the end of 2029, at a compound annual growth rate, or CAGR, of 24.0% from 2024 to 2029.
Neurology Devices: Global Markets
The global market for neurology devices is estimated to increase from $23.7 billion in 2023 to reach $31.7 billion by 2028, at a compound annual growth rate (CAGR) of 6.0% from 2023 through 2028.
Neurostimulation: Technologies and Global Markets
The global neurostimulation devices market should reach $11.7 billion by 2028 from $8.2 billion in 2023 at a compound annual growth rate (CAGR) of 7.4% for the forecast period of 2023 to 2028. Whereas the market was $7.7 billion in 2022 (base year).
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for Alzheimer's disease treatment should grow from $4.8 billion in 2020 to $6.3 billion by 2025 with a compound annual growth rate (CAGR) of 5.5% during the period of 2020-2025.
Recent Reports
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Global Market for Contract Research Organization (CRO) Services
The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Global Oncology Pharmaceuticals Market
The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.
Excipients in Pharmaceuticals: Global Markets to 2029
The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More